$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Oligonucleotides conjugated to protein-binding drugs

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • C12Q-001/68
  • C07H-021/04
  • C12N-015/85
출원번호 US-0334130 (1999-06-15)
발명자 / 주소
  • Manoharan, Muthiah
출원인 / 주소
  • ISIS Pharmaceuticals, Inc.
대리인 / 주소
    Woodcock Washburn LLP
인용정보 피인용 횟수 : 134  인용 특허 : 192

초록

Ligand-conjugated oligomeric compounds are described wherein ligands are conjugated to one or more sites on an oligomeric compound including the 2'-, 3'-, 5'-, nucleobase and internucleotide linkage sites. The ligand can be attached via an optional linking group. Ligands are selected for conjugation

대표청구항

1. An oligonucleotide covalently attached to an arylpropionic acid that interacts with human serum albumin, wherein the arylpropionic acid is selected from the group consisting of ibuprofen, suprofen, ketoprofen, (S)-(+)-pranoprofen, and carprofen. 2. The oligonucleotide of claim 1 wherein said

이 특허에 인용된 특허 (192)

  1. Tkachuk Zenovy (Kiev SUX) Kvasyuk Eugeny (Kiev SUX) Matsuka Gennady (Kiev SUX) Mikhailopulo Igor (Kiev SUX), (2′-5′) oligoadenylate analogues useful as inhibitors of host-v5.-graft response.
  2. Cook Phillip Dan ; Manoharan Muthiah ; Kawasaki Andrew Mamoru, 2'-O-aminooxy-modified oligonucleotides.
  3. Cook Phillip Dan ; Kawasaki Andrew Mamoru, 2'-modified oligonucleotides.
  4. Huynh Dinh Tam (Croissy/Seine FRX) Gouyette Catherine (Vanves FRX) Igolen Jean (Le Mesnil St. Denis FRX), 2,N6-disubstituted and 2,N6-trisubstituted adenosine-3′-phosphoramidites.
  5. Buhr Chris A. (Daly City CA) Matteucci Mark (Burlingame CA), 2\modified nucleoside and nucleotide compounds.
  6. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), 2′,5′-phosphorothioate oligoadenylates and their covalent conjugates with polylysine.
  7. Montgomery John A. (Birmingham AL) Secrist ; III John A. (Birmingham AL), 2′-deoxy-4′-thioribonucleosides and their antiviral activity.
  8. Usman Nassim (Boulder CO) Karpeisky Alexander (Boulder CO) Beigelman Leonid (Longmont CO) Modak Anil (Boulder CO), 2′deoxy-2′-alkylnucleotide containing nucleic acid.
  9. Cook P. Dan (Carlsbad CA) Acevedo Oscar L. (San Diego CA) Andrews Robert S. (San Juan Capistrano CA), 3-deazapurines.
  10. Cook P. Dan (Carlsbad CA) Acevedo Oscar L. (San Diego CA) Andrews Robert S. (San Juan Capistrano CA), 3-deazapurines.
  11. Cook Philip D. (Carlsbad CA) Delecki Daniel J. (Radnor PA) Guinosso Charles (Vista CA), Acyclic nucleoside analogs and oligonucleotide sequences containing them.
  12. Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR) Stirchak Eugene P. (Corvallis OR), Alpha-morpholino ribonucleoside derivatives and polymers thereof.
  13. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Aminoalkylphosphorothioamidate oligonucleotide deratives.
  14. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Aminoalkylphosphotriester oligonucleotide derivatives.
  15. Manoharan Muthiah ; Cook Phillip Dan ; Prakash Thazha P. ; Kawasaki Andrew M., Aminooxy-modified oligonucleotides and methods for making same.
  16. Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Anthraquinone-derivatives oligonucleotides.
  17. Gewirtz Alan M. (Philadelphia PA) Calabretta Bruno (Philadelphia PA), Antisence oligonucleotides to c-myb proto-oncogene and uses thereof.
  18. Baker Brenda ; Bennett C. Frank ; Anderson Kevin P., Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
  19. Ecker David J. (Carlsbad CA), Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides.
  20. Pagano Joseph S. (Chapel Hill NC) Traub Nancy R. (Raleigh NC) Lin Jung-Chung (Atlanta GA), Antisense oligonucleotides against Epstein-Barr virus.
  21. Switzer Christopher (Moreno Valley CA), Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides.
  22. Draper Kenneth G. (Madison NJ), Antiviral oligomers.
  23. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (Carlsbad CA), Backbone modified oligonucleotide analogs.
  24. De Mesmaeker Alain (Kaenerkinden CHX) Lebreton Jacques (Marseilles FRX) Waldner Adrian (Allschwil CHX) Cook Phillip D. (Carlsbad CA), Backbone modified oligonucleotide analogs.
  25. Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Backbone modified oligonucleotide analogs and preparation thereof through reductive coupling.
  26. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Morvan Francois (Montpellier FRX), Backbone modified oligonucleotide analogs and solid phase synthesis thereof.
  27. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA) Vasseur Jean J. (San Marcos CA) Debart Francoise (Montpellier FRX), Backbone modified oligonucleotide analogues.
  28. Sanghvi Yogesh S. (San Marcos CA) Cook Phillip D. (Vista CA), Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling.
  29. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  30. Leumann Christian (Zurich CHX), Bicyclic nucleosides, oligonucleotides, process for their preparation and intermediates.
  31. Matteucci Mark D. (Burlingame CA) Cao Xiaodong (Carlsbad CA), Binding compentent oligomers containing unsaturated 3′,5′and 2′,5′linkages.
  32. Tomalia Donald A. ; Baker James R. ; Cheng Roberta C. ; Bielinska Anna U. ; Fazio Michael J. ; Hedstrand David M. ; Johnson Jennifer A. ; Kaplan ; deceased Donald A. ; Klakamp Scott L. ; Kruper ; Jr., Bioactive and/or targeted dendrimer conjugates.
  33. Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Ramsay Shaw Barbara (Durham NC), Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same.
  34. Spielvogel Bernard F. (107 Wood Glen Dr. Cary NC 27511) Sood Anup (5041 Gatewood Dr. Durham NC 27712), Boronated phosphoramidate compounds.
  35. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  36. Altmann Karl-Heinz (Basel CHX) Imwinkelried Rene (Brig-Glis CHX) Eschenmoser Albert (Kusnacht CHX), Carbocyclic nucleosides containing bicyclic rings, oligonucleotides therefrom, process for their preparation, their use.
  37. Wu George Y. (Bloomfield CT) Wu Catherine H. (Bloomfield CT), Carrier system and method for the introduction of genes into mammalian cells.
  38. Letsinger Robert L. (Wilmette IL), Cholesteryl modified oligonucleotides.
  39. Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent (Austin TX), Chromophore probe for detection of nucleic acid.
  40. Bertsch-Frank Birgit (Rheinfelden DEX) Klasen Claas-Juergen (Freigericht DEX) Lieser Thomas (Hapau DEX) Mueller Klaus (Hasselroth DEX) Bewersdorf Martin (Gelnhausen DEX), Coated sodium percarbonate particles, a process for their production and detergent, cleaning and bleaching compositions.
  41. Hale Ron L. (Woodside CA) Lu Amy (Los Altos CA) Solas Dennis (San Francisco CA) Selick Harold E. (Belmont CA) Oldenburg Kevin R. (Fremont CA) Zaffaroni Alejandro C. (Atherton CA), Compositions and methods for enhanced drug delivery.
  42. Snitman David L. (Boulder CO), Compositions and methods for functionalizing nucleic acids.
  43. Cook Phillip Dan ; Ecker David J. ; Guinosso Charles John ; Acevedo Oscar Leobardo ; Kawasaki Andrew ; Ramasamy Kandasamy, Compound for detecting and modulating RNA activity and gene expression.
  44. Kmiec Eric B. (Malvern PA), Compounds and methods for site directed mutations in eukaryotic cells.
  45. Ohtsuka Eiko (Sappro JPX) Inoue Hideo (Sappro JPX) Morisawa Hirokazu (Kawasaki JPX) Shibahara Susumu (Kawasaki JPX) Mukai Sachiko (Kawasaki JPX) Nishihara Tohru (Kurashiki JPX), Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and st.
  46. Cook Phillip D. (San Marcos CA) Teng Kelly (San Diego CA), Conjugated 4′-desmethyl nucleoside analog compounds.
  47. Linn C. Preston (Durham NC) Pitner J. Bruce (Durham NC) Mize Pat D. (Durham NC), Covalent cyanine dye oligonucleotide conjugates.
  48. Cook Phillip D. (Carlsbad CA) Baschang Gerhard (Bettingen CHX), Cyclobutyl oligonucleotide surrogates.
  49. Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), DNA-reporter conjugates linked via the 2′or 5′-primary amino group of the 5′-terminal nucleoside.
  50. Baxter Anthony D. (Northwich GB2) Baylis Eric K. (Stockport GB2) Collingwood Stephen P. (Westhoughton GB2) Taylor Roger J. (Stretford GB2) De Mesmaeker Alain (Kanerkinden CHX) Schmit Chantal (Basel C, Dinucleoside phosphinates and their pharmaceutical compositions.
  51. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Konstanz DEX), Dual action 2′,5′-oligoadenylate antiviral derivatives and uses thereof.
  52. Suhadolnik Robert J. (Roslyn PA) Pfleiderer Wolfgang (Constance DEX), Encapsulated 2′,5′-phosphorothioate oligoadenylates.
  53. Brakel Christine L. (Brightwaters NY) Cook Alan F. (Cedar Groove NJ) Vuocolo Edmund (Bronx NY), End labeled nucleotide probe.
  54. Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
  55. Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Exonuclease resistant terminally substituted oligonucleotides.
  56. Froehler Brian C. (Belmont CA), Exonuclease-resistant oligonucleotides.
  57. Brush Charles K. (Whitefish Bay WI), Fluorescein labelled phosphoramidites.
  58. Cook Phillip Dan ; Monia Brett P., Gapped 2' modified oligonucleotides.
  59. Cook Phillip D. (Vista CA) Monia Brett P. (Carlsbad CA), Gapped 2′modified oligonucleotides.
  60. Cook Phillip D. (Carlsbad CA) Sanghvi Yogesh S. (Carlsbad CA), Heteroatomic oligonucleoside linkages.
  61. Teng Kelly (San Diego CA) Sanghvi Yogesh S. (San Marcos CA) Cook Phillip Dan (San Marcos CA), Heteroatomic oligonucleoside linkages.
  62. Metelev Valeri (Shrewsbury MA) Agrawal Sudhir (Shrewsbury MA), Hybrid oligonucleotide phosphorothioates.
  63. Rogers Thomas E. (Manchester MO) Gray Steven H. (Ellisville MO) Devadas Balekudru (Chesterfield MO) Adams Steven P. (St. Charles MO), Improved probes using nucleosides containing 3-dezauracil analogs.
  64. Goodchild John (Worcester MA) Zamecnik Paul C. (Shrewsbury MA), Inhibition of HTLV-III by exogenous oligonucleotides.
  65. Agrawal Sudhir (Shrewsbury MA) Leiter Josef M. E. (Brooklyn NY) Palese Peter (Leonia NJ) Zamecnik Paul C. (Shrewsbury MA), Inhibition of influenza virus replication by oligonucleotide phosphorothioates.
  66. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  67. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke She L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  68. Cohen Jack S. (Bethesda MD) Neckers Len (Bethesda MD) Stein Cy (Gaithersburg MD) Loke Shee L. (Wheaton MD) Shinozuka Kazuo (Kazo JPX), Inhibitors for replication of retroviruses and for the expression of oncogene products.
  69. Burch Ronald M. (Silver Spring MD), Interleukin receptor expression inhibiting antisense oligonucleotides.
  70. Agrawal Sudhir (Shrewsbury MA), Inverted chimeric and hybrid oligonucleotides.
  71. Ravikumar Vasulinga (Carlsbad CA) Mohan Venkatraman (Carlsbad CA), Lactam nucleic acids.
  72. Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Shrewsbury MA), Linear aminoalkylphosphoramidate oligonucleotide derivatives.
  73. Miller Paul S. (Baltimore MD) Ts\O Paul O. P. (Lutherville MD), Linkage of proteins to nucleic acids.
  74. Arnold ; Jr. Lyle J. (San Diego CA) Reynolds Mark A. (San Diego CA) Bhatt Ram S. (San Diego CA), Linking reagents for nucleotide probes.
  75. Brown Richard Hunter (Chesham GB2), Liquid level sensor.
  76. Blaney Jeffrey M. ; Cohen Fred, Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyret.
  77. Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
  78. Benner Steven A. (Hadlaubstrasse 151 CH-8006 Zurich CHX), Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases.
  79. Kaji Akira (1-9 ; Daimoncho 1-chome Higashikurume-shi ; Tokyo JPX), Method for inhibiting propagation of virus and anti-viral agent.
  80. Magda Darren (Cupertino CA) Sessler Jonathan L. (Austin TX) Iverson Brent L. (Austin TX) Sansom Petra I. (Austin TX) Crofts Shaun P. (Campbell CA), Method of expanded porphyrin-oligonucleotide conjugate synthesis.
  81. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  82. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  83. Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
  84. Smith Larry J. (Houston TX), Methods and compositions for treatment of cancer using oligonucleotides.
  85. Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA) Eder Paul S. (Iowa City IA) Dagle John M. (Iowa City IA), Methods for blocking the expression of specifically targeted genes.
  86. Cook Phillip Dan (Vista CA) Teng Kelly (San Diego CA), Methods of making conjugated 4′desmethyl nucleoside analog compounds.
  87. Matteucci Mark (Burlingame CA) Jones Robert J. (Daly City CA) Munger John (San Francisco CA), Modified internucleoside linkages having one nitrogen and two carbon atoms.
  88. Pieles Uwe (Gttingen DEX) Englisch Uwe (Gttingen DEX) Cramer Friedrich (Gttingen DEX), Modified oligonucleotides.
  89. Beaton Graham (Boulder CO) Fisher Eric F. (Boulder CO), Modified oligonucleotides and intermediates useful in nucleic acid therapeutics.
  90. Cook Phillip D. (Carlsbad CA), Monomers for preparation of oligonucleotides having chiral phosphorus linkages.
  91. Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Multifunctional nucleic acid monomer.
  92. Cook P. Dan (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), N-2 substituted purines.
  93. Chang Chu-An (Piedmont CA) Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith.
  94. Chang Chu-An (Piedmont CA) Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith.
  95. Nelson Paul S. (Union City CA) Kent Mark A. (Sunnyvale CA), Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides.
  96. Lin Kuei-Ying (Fremont CA) Matteucci Mark (Burlingame CA), Non-nucleoside linkers for convenient attachment of labels to oligonucleotides using standard synthetic methods.
  97. Shizuya Hiroaki (1632 Indiana Ave. South Pasadena CA 91030) Millar Sharon L. (1825 Lanai St. West Covina CA 91792), Non-radioisotope tagging of fragments.
  98. Ts\o Paul O. P. (2117 Folkstone Rd. Lutherville MD 21093) Miller Paul S. (225 Hopkins Rd. Baltimore MD 21212), Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof.
  99. Tullis Richard H. (Leucadia CA), Novel amphiphilic nucleic acid conjugates.
  100. Nguyen Thanh T. (Tigy FRX) Helene Claude (Saint Cyr en Val FRX) Asseline Ulysse (La Source FRX), Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis a.
  101. Weis Alexander L. (Berwyn PA) Oakes Fred T. (Rochester NY) Hausheer Frederick H. (San Antonio TX) Cavanaugh ; Jr. Paul F. (West Chester PA) Moskwa Patricia S. (Phoenixville PA), Nuclease resistant compounds.
  102. Cook Philip D. (Carlsbad CA) Sanghvi Yogesh S. (San Marcos CA), Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression.
  103. Walder Joseph A. (Iowa City IA) Walder Roxanne Y. (Iowa City IA), Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled.
  104. Bischofberger Norbert W. (San Carlos CA) Matteucci Mark D. (Burlingame CA), Nucleic acid intercalating agents.
  105. Ramachandran Kuzhalmannam L. (Natick MA) Cate Richard L. (Plymouth MA), Nucleic acid probe linked to a label having a terminal cysteine.
  106. Rokita Steven E. (Port Jefferson NY) Chatterjee Moneesh (Stony Brook NY), Nucleic acids labeled with naphthoquinone probe.
  107. Haralambidis Jim (Victoria AUX), Nucleoside derivatives.
  108. Klevan Leonard (Washington DC) Gebeyehu Gulilat (Silver Spring MD) Rao Prasad Y. (Damascus MD), Nucleotide analogs for nucleic acid labeling and detection.
  109. Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Nucleotides for introducing selectably cleavable and/or abasic sites into oligonucleotides.
  110. Meyer ; Jr. Rich B. (Woodinville WA) Adams A. David (Snohomish WA) Petrie Charles R. (Woodinville WA), Oligo (aa 상세보기
  • Letsinger Robert L. (Wilmette IL) Gryaznov Sergei M. (San Mateo CA), Oligodeoxyribonucleotides including 3′-aminonucleoside-phosphoramidate linkages and terminal 3′-amino groups.
  • Cook Phillip Dan ; Sanghvi Yogesh S. ; Sprankle Kelly G. ; Ross Bruce S. ; Griffey Rich H., Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions.
  • Sanghvi Yogesh S. (Carlsbad CA) Cook Phillip D. (Carlsbad CA), Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms.
  • Hecht Sidney M. (Charlottesville VA), Oligonucleotide N-alkylphosphoramidates.
  • Bischofberger Norbert (San Carlos CA) Kent Ken (Mountain View CA) Wagner Rick (Burlingame CA) Buhr Chris (Daly City CA) Lin Kuei-Ying (Fremont CA), Oligonucleotide analogs capable of passive cell membrane permeation.
  • Benner Steven A. (Grossmannstrasse 16 ; #7 CH-8049 Zurich CHX), Oligonucleotide analogs containing sulfur linkages.
  • Matteucci Mark (Burlingame CA), Oligonucleotide analogs with novel linkages.
  • Matteucci Mark (Burlingame CA), Oligonucleotide analogs with novel linkages.
  • Huie Edward M. (Wilmington DE) Trainor George L. (Wilmington DE), Oligonucleotide analogs with sulfamate linkages.
  • Weis Alexander Ludvik (Berwyn PA) Hausheer Frederick Herman (San Antonio TX) Chaturvedula Prasad Venkata Chala (Exton PA) Delecki Daniel Joseph (Radnor PA) Cavanaugh ; Jr. Paul Francis (West Chester , Oligonucleotide analogues containing phosphate diester linkage substitutes, compositions thereof, and precursor dinucleo.
  • Priest John H. (Everett WA), Oligonucleotide conjugates.
  • Miyoshi Kenichi (Hiroshima JPX) Fuwa Toru (Hiroshima JPX), Oligonucleotide derivatives.
  • Miyoshi Kenichi (Hiroshima JPX) Suzuki Masanori (Hiroshima JPX) Fuwa Toru (Hiroshima JPX), Oligonucleotide derivatives.
  • Miyoshi Kenichi (Hiroshima JPX) Fuwa Toru (Hiroshima JPX), Oligonucleotide derivatives and production thereof.
  • Chaturvedula Prasad Venkata Chala (Exton PA), Oligonucleotide dimers with amide linkages replacing phosphodiester linkages.
  • Buhr Chris A. (Daly City CA), Oligonucleotide having enhanced binding affinity.
  • Agrawal Sudhir (Shrewsbury MA) Tang Jin-Yan (Worcester MA), Oligonucleotide multiple reporter precursors.
  • Tullis Richard H. (La Jolla CA), Oligonucleotide therapeutic agent and method of making same.
  • Warren ; III Harold C. (Rush NY) Oakes Fred T. (Rochester NY), Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction proce.
  • Hornes Erik (Oslo NOX) Korsnes Lars (Oslo NOX), Oligonucleotide-linked magnetic particles and uses thereof.
  • Haralambidis Jim (Box Hill South AUX) Tregear Geoffrey W. (Hawthorn AUX), Oligonucleotide-polyamide conjugates and methods of production and applications of the same.
  • Maag Hans (Menlo Park CA) Rose Samuel J. (Mountain View CA) Schmidt Beat (Baltschieder CHX), Oligonucleotides containing 4′-substituted nucleotides.
  • Gmeiner William H. (Omaha NE) Iversen Patrick L. (Omaha NE), Oligonucleotides containing 5-fluorouracil.
  • Froehler Brian (Belmont CA) Jones Robert J. (Daly City CA), Oligonucleotides containing 5-propynyl pyrimidines.
  • Cook Phillip D. (San Marcos CA) Ramasamy Kanda S. (Laguna Hills CA) Manoharan Muthiah (Carlsbad CA), Oligonucleotides containing N-2 substituted purines.
  • Cook Phillip D. (San Marcos CA) Hoke Glenn (Mt. Airy MD), Oligonucleotides having phosphorothioate linkages of high chiral purity.
  • Cook Phillip D. (San Marcos CA) Hoke Glenn (Mt. Airy MD), Oligonucleotides having phosphorothioate linkages of high chiral purity.
  • Smith Lloyd M. (South Pasadena CA) Fung Steven (Palo Alto CA) Kaiser ; Jr. Robert J. (Glendale CA), Oligonucleotides possessing a primary amino group in the terminal nucleotide.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Oligonucleotides with cleavable sites.
  • Froehler Brian (Belmont CA), Oligonucleotides with inverted polarity.
  • Lebleu Bernard (Montpellier FRX) Bayard Bernard (Castelnau Le Lez FRX), Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Oligonucleotides with selectably cleavable and/or abasic sites.
  • Imbach Jean-Louis (Montpellier FRX) Gosselin Gilles J. M. (Montpellier FRX), Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon.
  • Spielvogel Bernard F. (Raleigh NC) Sood Anup (Durham NC) Hall Iris H. (Chapel Hill NC) Shaw Barbara R. (Durham NC), Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates.
  • Barascut Jean-Louis (Combaillaux FRX) Imbach Jean-Louis (Montpellier FRX), Oligothionucleotides.
  • Cook Phillip Dan (Carlsbad CA), PNA-DNA-PNA chimeric macromolecules.
  • Meyer ; Jr. Rich B. (Woodinville WA) Gall Alexander A. (Bothell WA) Reed Michael W. (Seattle WA), Peptide linkers for improved oligonucleotide delivery.
  • Nielsen Peter E. (Hjortevanget 509 DK 2980 Kokkedal DKX) Buchardt Ole (Sondergardsvej 73 DK 3500 Vaerlose DKX) Egholm Michael (Johnstrup Alle 3 DK 1923 Frederiksberg DKX) Berg Rolf H. (Strandvaenget , Peptide nucleic acids.
  • Buchardt ; deceased Ole,DKX ; Buchardt ; legal representative by Dorte,DKX ; Egholm Michael ; Nielsen Peter Eigil,DKX ; Berg Rolf Henrik,DKX, Peptide nucleic acids having amino acid side chains.
  • Buchardt ; deceased Ole,DKX ; Buchardt ; representative by Dorte,DKX ; Egholm Michael ; Nielsen Peter Eigil,DKX ; Berg Rolf Henrik,DKX, Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility.
  • Misiura Konrad (Lodz PLX) Gait Michael (Cambridge GB3), Phosphoramidite derivatives, their preparation and the use thereof in the incorporation of reporter groups on synthetic.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Photolabile reagents for incorporation into oligonucleotide chains.
  • Yamane Akio (Hiroshima JPX) Kawasoe Tatsuro (Hiroshima JPX) Tsukumo Noriko (Hiroshima JPX) Miyoshi Kenichi (Hiroshima JPX), Poly-labelled oligonucleotide derivative.
  • Cook Philip D. (Carlsbad CA) Guinosso Charles J. (Carlsbad CA), Polyamine conjugated oligonucleotides.
  • Cook Philip D. (Carlsbad CA) Guinosso Charles J. (Carlsbad CA), Polyamine conjugated oligonucleotides.
  • Maddry Joseph A. (Birmingham AL) Reynolds Robert C. (Birmingham AL) Secrist John A. (Birmingham AL) Montgomery John A. (Birmingham AL) Crooks Peter A. (Lexington KY), Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages.
  • Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO) Brill Wolfgang (Freiburg DEX) Nielsen John (Horsholm DKX), Polynucleotide phosphorodithioate.
  • Caruthers Marvin H. (Boulder CO) Marshall William S. (Boulder CO), Polynucleotide phosphorodithioates.
  • Urdea Michael S. (Alamo CA) Horn Thomas (Berkeley CA), Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use.
  • Blaschke Gottfried (Mnster DEX) Schulte Karl-Ernst (Mnster DEX), Process for obtaining enantiomers of 2-arylpropionic acids.
  • Cook Phillip D. (Carlsbad CA), Process for preparing oligonucleotides having chiral phosphorus linkages.
  • McGee Daniel P. C. (Carlsbad CA), Process for the preparation of 2′-O-alkyl guanosine and related compounds.
  • McGee Daniel Peter Claude (Boulder CO), Process for the preparation of 2′-O-alkyl purine phosphoramidites.
  • Weis Alexander L. (Berwyn PA) Saha Ashis K. (Frazer PA) Hausheer Frederick H. (San Antonio TX), Process of linking nucleosides with a siloxane bridge.
  • Hawkins Mary E. (Potomac MD) Pfleiderer Wolfgang (Konstanz MD DEX) Davis Michael D. (Rockville MD) Balis Frank (Bethesda MD), Pteridine nucleotide analogs as fluorescent DNA probes.
  • Matteucci Mark D. (Burlingame CA) Jones Robert J. (Millbrae CA) Lin Kuei-Ying (Fremont CA), Pyrimidine derivatives for labeled binding partners.
  • Acevedo Oscar L. (San Diego CA) Hebert Normand (San Marcos CA), Pyrrolidine-containing monomers and oligomers.
  • Manoharan Muthiah ; Mohan Venkatraman ; Boswell Herb, RNA targeted 2'-modified oligonucleotides that are conformationally preorganized.
  • Hobbs ; Jr. Frank W. (Wilmington DE), Reagents for the preparation of 5′-tagged oligonucleotides.
  • Haseloff James P. (O\Connor AUX) Gerlach Wayne L. (Hughes AUX) Jennings Philip A. (West Chatswood AUX) Cameron Fiona H. (Forestville AUX), Ribozymes.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Sequence-specific binding polymers for duplex nucleic acids.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Sequence-specific binding polymers for duplex nucleic acids.
  • Ruth Jerry L. (San Diego CA), Single-stranded labelled oligonucleotides of preselected sequence.
  • Ruth Jerry L. (San Diego CA), Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis.
  • Agrawal, Sudhir; Tang, Jinyan, Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling.
  • Van Ness Jeffrey (Bothell WA) Petrie Charles R. (Woodinville WA) Tabone John C. (Bothell WA) Vermeulen Nicolaas M. J. (Woodinville WA), Solid supports for nucleic acid hybridization assays.
  • Gordon Julian (307 E. Sheridan Rd. Lake Bluft IL 60044) Minks Michael A. (Biochemistry Dept. ; University of the Witwatersrand ; 1 Jan Smuts Ave Johannesburg 2001 ZAX), Specific antibody to the native form of 2′5′-oligonucleotides, the method of preparation and the use as reagents in im.
  • Goodchild John (Westborough MA) Nesbitt Steven M. (Worcester MA), Stabilized ribozyme analogs.
  • Letsinger Robert L. (Wilmetter IL), Steroid modified oligonucleotides.
  • Cook Phillip Dan (Carlsbad CA) Manoharan Muthiah (Carlsbad CA) Ramasamy Kanda S. (Laguna Hills CA), Substituted purines and oligonucleotide cross-linking.
  • Cook Phillip Dan (Carlsbad CA) Kawasaki Andrew Mamoro (Oceanside CA), Sugar modified oligonucleotides that detect and modulate gene expression.
  • Holt Gary (11736 S. Dry Creek Rd. Sandy UT 84090), Surface cleaner and treatment.
  • Cook P. Dan ; Acevedo Oscar L. ; Andrews Robert S., Synthesis of 3-deazapurines.
  • Ravikumar Vasulinga (Carlsbad CA) Cole Douglas L. (San Diego CA), Synthesis of oligonucleotides.
  • Wickham Thomas J. ; Roelvink Petrus W. ; Kovesdi Imre, Targeting adenovirus with use of constrained peptide motifs.
  • Hemmi Gregory W. (Sunnyvale CA) Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA), Texaphyrin compounds having improved functionalization.
  • Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA), Texaphyrin metal complexes having improved functionalization.
  • Sessler Jonathan L. (Austin TX) Mody Tarak D. (Sunnyvale CA) Hemmi Gregory W. (Sunnyvale CA) Kral Vladimir A. (Austin TX) Magda Darren (Cupertino CA), Texaphyrin-oligonucleotide conjugates.
  • Cook Phillip D. (Carlsbad CA) Manoharan Muthiah (Carlsbad CA), Thiol-derivatized nucleosides.
  • Reed Michael W. (3575 NE. 180th Seattle WA 98105) Meyer ; Jr. Rich B. (15411 NE. 176th Pl. Woodinville WA 98072), Trifunctional intermediates for preparing 3′-tailed oligonucleotides.
  • Summerton, James E.; Weller, Dwight D., Uncharged morpholino-based polymers having achiral intersubunit linkages.
  • Summerton James E. (Corvallis OR) Weller Dwight D. (Corvallis OR), Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages.
  • 이 특허를 인용한 특허 (134)

    1. Prakash, Thazha P.; Baker, Brenda F.; Eldrup, Anne B.; Manoharan, Muthiah; Bhat, Balkrishen; Griffey, Richard; Swayze, Eric E.; Crooke, Stanley T., 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations.
    2. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda, Antagonat compositions and methods of use.
    3. Karelson, Mati; Saarma, Mart; Pilv, Mehis, Antisense agents combining strongly bound base-modified oligonucleotide and artificial nuclease.
    4. Gegg, Jr., Colin V.; Johnson, Eileen J.; Miranda, Leslie P.; Walker, Kenneth W.; Holder, Jerry Ryan; Wright, Marie E.; D'Amico, Derin C., CGRP peptide antagonists and conjugates.
    5. Crooke, Stanley T., Chimeric oligomeric compounds and their use in gene modulation.
    6. Jaeger, Laura B.; Nath, Avindra; Major, Eugene; Kushner-Monaco, Maria Chiara; Ferenczy, Michael W., Compositions and methods for inhibiting JC virus (JCV).
    7. Karras, James G.; Gregory, Susan; Crosby, Jeffrey R.; Guha, Mausumee; Tung, David; Freier, Susan M., Compositions and their uses directed to IL-4R alpha.
    8. Karras,James G.; Gregory,Susan; Freier,Susan M.; Gaarde,William A.; Guha,Mausumee, Compositions and their uses directed to IL-4R alpha.
    9. Allerson, Charles; Bhat, Balkrishen; Eldrup, Anne B.; Manoharan, Muthiah; Griffey, Richard H.; Baker, Brenda F.; Swayze, Eric E., Compositions comprising alternating 2'-modified nucleosides for use in gene modulation.
    10. Allerson, Charles; Bhat, Balkrishen; Eldrup, Anne B.; Manoharan, Muthiah; Griffey, Richard H.; Baker, Brenda F.; Swayze, Eric E., Compositions comprising alternating 2′-modified nucleosides for use in gene modulation.
    11. Bennett, C. Frank; McKay, Robert; Monia, Brett P.; Baker, Brenda F.; Sioufi, Namir, Conjugates for use in hepatocyte free uptake assays.
    12. Mirkin, Chad A.; Paller, Amy S.; Giljohann, David A., Delivery of oligonucleotide functionalized nanoparticles.
    13. Monia, Brett P.; Freier, Susan M.; Siwkowski, Andrew M.; Guo, Shuling, Diagnosis and treatment of disease.
    14. Baker, Brenda F.; Kraynack, Bryan A., Double stranded constructs comprising one or more short strands hybridized to a longer strand.
    15. Kamens, Joanne; Khvorova, Anastasia, Inhibition of PCSK9 through RNAI.
    16. Gleave, Martin E.; Ischia, Joseph, Method for treatment of castration-resistant prostate cancer.
    17. Bhanot, Sanjay; Dobie, Kenneth W.; Jain, Ravi, Modulation of eIF4E-BP2 expression.
    18. Bhanot, Sanjay; Dobie, Kenneth W.; Jain, Ravi, Modulation of eIF4E-BP2 expression.
    19. Bhanot,Sanjay; Dobie,Kenneth W.; Jain,Ravi, Modulation of eIF4E-BP2 expression.
    20. Brown-Driver, Vickie L.; Jain, Ravi, Modulation of transthyretin expression.
    21. Freier, Susan M., Modulation of transthyretin expression.
    22. Monia, Brett P.; Freier, Susan M.; Siwkowski, Andrew M.; Guo, Shuling, Modulation of transthyretin expression.
    23. Mirkin, Chad A.; Ko, Caroline H.; Stegh, Alexander; Giljohann, David A.; Luciano, Janina; Jensen, Samuel A., Nanoconjugates able to cross the blood-brain barrier.
    24. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
    25. Wahlestedt, Claes, Natural antisense and non-coding RNA transcripts as drug targets.
    26. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Miller, Michelle; Bulock, Karen G., Neutral nanotransporters.
    27. Mirkin, Chad A.; Giljohann, David A.; Seferos, Dwight, Nucleic acid functionalized nanoparticles for therapeutic applications.
    28. Mirkin, Chad A.; Rosi, Nathaniel L.; Thaxton, C. Shad; Giljohann, David A., Nucleic acid functionalized nanoparticles for therapeutic applications.
    29. Mirkin, Chad A.; Rosi, Nathaniel L.; Thaxton, C. Shad; Giljohann, David A., Nucleic acid functionalized nanoparticles for therapeutic applications.
    30. Mirkin, Chad A.; Rosi, Nathaniel L.; Thaxton, C. Shad; Giljohann, David A., Nucleic acid functionalized nonoparticles for therapeutic applications.
    31. Crooke, Stanley T., Oligoribonucleotides and ribonucleases for cleaving RNA.
    32. Mirkin, Chad A.; Seferos, Dwight S.; Giljohann, David A., Particles for detecting intracellular targets.
    33. Mirkin, Chad A.; Seferos, Dwight; Giljohann, David A., Particles for detecting intracellular targets.
    34. Samarsky, Dmitry; Woolf, Tod M., Phagocytic cell delivery of RNAI.
    35. Mirkin, Chad A.; Giljohann, David A.; Seferos, Dwight S.; Prigodich, Andrew E.; Patel, Pinal C., Polyvalent RNA-nanoparticle compositions.
    36. Mirkin, Chad A.; Giljohann, David A.; Seferos, Dwight; Prigodich, Andrew E.; Patel, Pinal C., Polyvalent RNA-nanoparticle compositions.
    37. Bhat, Balkrishen; Swayze, Eric E.; Prakash, Thazha P.; Allerson, Charles; Dande, Prasad; Griffey, Richard H., Positionally modified siRNA constructs.
    38. Hsieh, Huangpin Ben, Process for preparing albumin protein conjugated oligonucleotide probes.
    39. Woolf, Tod M.; Kamens, Joanne; Salomon, William; Khvorova, Anastasia, RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality.
    40. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Pavco, Pamela A.; Cardia, James, RNA interference in skin indications.
    41. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James, Reduced size self-delivering RNAi compounds.
    42. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James, Reduced size self-delivering RNAi compounds.
    43. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James, Reduced size self-delivering RNAi compounds.
    44. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James, Reduced size self-delivering RNAi compounds.
    45. Khvorova, Anastasia; Salomon, William; Kamens, Joanne; Samarsky, Dmitry; Woolf, Tod M.; Cardia, James, Reduced size self-delivering RNAi compounds.
    46. Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Kesavan, Venkitasamy, Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety.
    47. Manoharan, Muthiah; Rajeev, Kallanthottathil G.; Kesavan, Venkitasamy, Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety.
    48. Mirkin, Chad A.; Giljohann, David A.; Daniel, Weston L.; Cutler, Joshua I.; Zhang, Ke; Zheng, Dan, Templated nanoconjugates.
    49. Mirkin, Chad A.; Giljohann, David A.; Daniel, Weston L.; Cutler, Joshua I.; Zhang, Ke; Zheng, Dan, Templated nanoconjugates.
    50. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of 'IQ motif containing GTPase activating protein' (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    51. Collard, Joseph; Khorkova Sherman, Olga, Treatment of ABCA1 gene related diseases by inhibition of a natural antisense transcript to ABCA1.
    52. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ).
    53. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin.
    54. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    55. Collard, Joseph; Khorkova Sherman, Olga, Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT.
    56. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    57. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    58. Collard, Joseph; Khorkova Sherman, Olga, Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG.
    59. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    60. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    61. Collard, Joseph; Khorkova Sherman, Olga, Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4.
    62. Collard, Joseph; Khorkova Sherman, Olga, Treatment of Paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    63. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    64. Collard, Joseph; Khorkova Sherman, Olga, Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1.
    65. Collard, Joseph; Khorkova Sherman, Olga, Treatment of adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an adiponectin (ADIPOQ).
    66. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    67. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; Shen, Gang, Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA.
    68. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    69. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    70. Collard, Joseph; Khorkova Sherman, Olga, Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene.
    71. Collard, Joseph; Khorkova, Olga, Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1.
    72. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    73. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    74. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    75. Collard, Joseph; Khorkova Sherman, Olga, Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1.
    76. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
    77. Faghihi, Mohammad Ali; Coito, Carlos, Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF.
    78. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisene transcript to CSF3.
    79. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    80. Collard, Joseph; Khorkova Sherman, Olga, Treatment of colony-stimulating factor 3 (CSF3) related diseases by inhibition of natural antisense transcript to CSF3.
    81. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    82. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1.
    83. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    84. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    85. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of discs large homolog (DLG) related diseases by inhibition of natural antisense transcript to DLG.
    86. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    87. Collard, Joseph; Khorkova Sherman, Olga, Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene.
    88. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    89. Collard, Joseph; Khorkova Sherman, Olga, Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family.
    90. Collard, Joseph; Khorkova Sherman, Olga, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    91. Collard, Joseph; Sherman, Olga Khorkova, Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO.
    92. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    93. Collard, Joseph; Khorkova Sherman, Olga, Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21.
    94. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of filaggrin (FLG) related diseases by modulation of FLG expression and activity.
    95. Collard, Joseph; Khorkova Sherman, Olga, Treatment of frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN.
    96. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    97. Collard, Joseph; Khorkova Sherman, Olga, Treatment of hepatocyte growth factor (HGF) related diseases by inhibition of natural antisense transcript to HGF.
    98. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS).
    99. Collard, Joseph; Khorkova Sherman, Olga, Treatment of insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to IRS2 and transcription factor E3 (TFE3).
    100. Collard, Joseph; Khorkova Sherman, Olga, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    101. Collard, Joseph; Sherman, Olga Khorkova, Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8.
    102. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    103. Collard, Joseph; Khorkova Sherman, Olga, Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1.
    104. Collard, Joseph; Khorkova Sherman, Olga, Treatment of methionine sulfoxide reductase a (MSRA) related diseases by inhibition of natural antisense transcript to MSRA.
    105. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2.
    106. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    107. Collard, Joseph; Khorkova Sherman, Olga, Treatment of nuclear respiratory factor 1 (NRF1) related diseases by inhibition of natural antisense transcript to NRF1.
    108. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
    109. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene.
    110. Collard, Joseph; Khorkova Sherman, Olga, Treatment of paraoxonase 1 (PON1) related diseases by inhibition of natural antisense transcript to PON1.
    111. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related disease by inhibition of natural antisense transcript to PYCR1.
    112. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    113. Collard, Joseph; Khorkova Sherman, Olga, Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1.
    114. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    115. Collard, Joseph; Khorkova Sherman, Olga, Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor.
    116. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG.
    117. Collard, Joseph; Khorkova Sherman, Olga, Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4.
    118. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos; De Leon, Belinda, Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT).
    119. Collard, Joseph; Khorkova Sherman, Olga; De Leon, Belinda; Coito, Carlos; Hsiao, Jane H., Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA.
    120. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2 (IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    121. Collard, Joseph; Khorkova Sherman, Olga, Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3.
    122. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    123. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP.
    124. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    125. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2.
    126. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    127. Collard, Joseph; Khorkova Sherman, Olga, Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63.
    128. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    129. Collard, Joseph; Khorkova Sherman, Olga, Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2.
    130. Collard, Joseph; Khorkova Sherman, Olga, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    131. Collard, Joseph; Sherman, Olga Khorkova, Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF.
    132. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP.
    133. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘C terminus of HSP7O-interacting protein’ (CHIP) related diseases by inhibition of natural antisense transcript to CHIP.
    134. Collard, Joseph; Khorkova Sherman, Olga; Coito, Carlos, Treatment of ‘IQ motif containing gtpase activating protein’ (IQGAP) related diseases by inhibition of natural antisense transcript to IQGAP.
    섹션별 컨텐츠 바로가기

    AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

    AI-Helper 아이콘
    AI-Helper
    안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
    ※ AI-Helper는 부적절한 답변을 할 수 있습니다.

    선택된 텍스트